52 results about "Immunologic preparation" patented technology

The invention discloses a composite IgY antibody for resisting COVID-19 and SARS. The antibody is prepared by the following method: constructing a recombinant antigen of SARS-CoV-2 and SARS-CoV; preparing an immune preparation with the recombinant antigen to immunize egg-producing birds, and obtaining the specific composite IgY antibody from the immunized eggs. A spray prepared by the antibody canbe used for broad-spectrum killing of SARS-CoV-2 and SARS-CoV, and is suitable for spraying on nasal cavity, oral cavity, skin and other parts. The antibody preparation has a specific virus neutralizing effect, can effectively control infection sources, protect susceptible people, disinfect and protect first-line medical staff and prevent spread of SARS-CoV-2.

The invention relates to a bursin extracting method and its application to curing disease and immunity, having important value in application in the aspects of heightening organismal immunity and acting as immunoenhancer, heightening effect of vaccine, etc., and able to heighten body fluid and cell immune functions of mammal at the same time. It can be used to prevent and cure infectious diseases and young animal diseases singly or together with other drugs such as antivirus and antibacterial drugs or immunomodulators, also be applied to animal vaccine as adjuvant or immunoenhancer to strengthen the disease-resistant ability and immunoresponse ability to peculiar antigens, thus heightening the immune effect.

The invention discloses a Saddletail grouper antimicrobial peptide LEAP-2 gene, vector, recombinant strain and protein, and application thereof. The amino acid sequence of the Saddletail grouper antimicrobial peptide LEAP-2 precursor protein is disclosed as SEQ ID NO.2, or the Saddletail grouper antimicrobial peptide LEAP-2 precursor protein is a protein with identical or higher activity prepared by performing substitution, deletion and/or addition on one or more of amino acids and/or terminal modification on the amino acid sequence disclosed as SEQ ID NO.2. The invention also discloses a Saddletail grouper antimicrobial peptide LEAP-2 gene sequence and a LEAP-2 mature peptide gene mLEAP-2 nucleotide sequence subjected to code modification; and thus, the Saddletail grouper antimicrobial peptide LEAP-2 gene enriches the gene bank of grouper, can be used for preparing a recombinant protein, antimicrobial preparation, fish immune preparation or feed additive, and provides new theoretical and practical basis for physiologic immunity research of grouper.

A tacrolimus separation and purification method is provided. Two medium-pressure chromatographic devices are adopted. A tacrolimus fermentation extract liquid having low chromatographic purity is adopted as a raw material. Polysaccharides, protein, and other impurities are removed through a first chromatographic column; then a solvent used for extraction is removed through a rotary evaporation process; an obtained product is dissolved again; a tacrolimus-containing eluate having a low concentration is obtained by separation through a second chromatographic column; the eluates in a plurality ofbatches are combined; and the mixture is concentrated by a nanofiltration membrane to obtain high-purity solid-state tacrolimus. Through the method, direct purification from a tacrolimus-containing fermentation solution can be achieved, the tacrolimus purity is significantly increased, and medicine effects of immunologic preparations prepared from the tacrolimus are indirectly improved.

The invention discloses the usage of TolC protein. The TolC has strong serum reaction, is used to detect and diagnose dysentery, and is used as protective antigens to prepare vaccine.

The invention discloses recombinant serum amyloid A capable of enhancing immune response of crassostrea gigas. The recombinant serum amyloid A is characterized that the amino acid sequence is represented by SEQ ID NO. 1. Gene expression of cytokines CgIL17-1, CgIL17-5, and CgTNF in blood lymphocytes can be remarkably promoted inside and outside bodies of the crassostrea gigas, the immune responselevel of the crassostrea gigas can be enhanced, and the recombinant serum amyloid A has application value in preparation of novel immune preparations and other drugs for shellfishes, especially breeding shellfishes.

The invention relates to the field of animal immune preparations, in particular to an adenitis equorum disease inactivation vaccine and a preparation method thereof. The adenitis equorum disease inactivation vaccine is prepared by taking a high-generation culture strain ES14-09 of an adenitis equorum streptococ cus Erdos epidemic strain ES14 as specific immunizing antigen through processes of seed batch preparation, culture, concentration, inactivation and adjuvant emulsification. The content of antigen bacteria of the adenitis equorum disease inactivation vaccine is 5*10<8>/ml. The adenitis equorum disease inactivation vaccine is high in protection rate and applicable to epidemic prevention of adenitis equorum diseases of equine animals.

The invention relates to a bidirectional oil emulsion agent used in immunity agent, which comprises animal injection white oil, Siban 80, tuwen 80, stabilizer 1.2 propanediol, activator PVP polyvinyl pyrrolidon. And the production comprises that in room temperature, first emulsifying animal injection white oil in an emulsifying pot, to obtain light liquid wax oil, to be added with the lipophilic SIban-80, to be mixed for 3-7min at 75-80r/min speed until foam disappears and transparent, then mixing and adding hydrophilic tuwen-80 to be mixed for 3-7min uniformly, adding 1.2 propanediol, mixing uniformly, adding polyvinyl pyrrolidon until foam disappears and transparent, laying for 25-35min. The invention has low viscidity, injection support, uniform size, and adsorption support, with high stability, long service life, and the color in white or milky white with some pink.

The invention relates to the technical field of bioactive peptides and provides application of a tilapia protein peptide to preparation of an immune preparation. The tilapia protein peptide refers toenzymolysis polypeptide obtained by enzymolysis of tilapia protein. According to researches, the tilapia protein peptide is capable of effectively inducing RAW264.7 cell iNOS expression and increasingNO release amount, and due to dose dependence, the tilapia protein peptide is excellent in immunoregulatory activity and can be used as a raw material for the immune preparation. Further, according to the researches, the tilapia protein peptide has no evident influences on RAW264.7 cell activity under immunoregulatory dosage, namely the tilapia protein peptide has no cytotoxicity when giving playto an immunoregulatory effect. The tilapia protein peptide is preferably derived from enzymatic hydrolysates of tilapia leftovers, and a novel application approach is provided for recycling of tilapia byproducts.

The present invention provides a biological product capable of resisting stenotrophomonas maltophilia and Pseudomonas aeruginosa infection and raising the body fluid immunity and cell immunity of malignant tumor patient. The biological product is prepared with stenotrophomonas maltophilia, and may be prepared into various kinds of immunological preparations and immune regulating preparations. The medicine of the present invention has the special effect of preventing and treating stenotrophomonas maltophilia and Pseudomonas aeruginosa infection and treating ascites carcinoma and leukemia.

The invention refers to a nucleic acid compound, the producing method and the application at the aspect of making immune preparation, produced by making copolymerization or covalence reaction on nucleic acid segment, multi-peptide and water-solubility multi-polymer under catalysis. It has the common formula; nucleic acid/multi-peptide/water-solubility multi-polymer. It can protect the organism to resist the pathogene infection, resist the tumour and cure the independent immune diseases and effectively inspires the immune response of organism.

The invention relates to a biological immune preparation for strengthening a goatpox vaccine antibody and a manufacturing method of the biological immune preparation. The steps adopted in the method include that the fresh spleen of a healthy yak is selected, after fat, the envelope and the internal connective tissue are removed, the spleen is subjected to freezing preservation, the yak spleen obtained after freezing preservation is taken out and melted and is minced through a tissue stamp mill, after sterile tri-distilled water with the same weight is added, the high-speed tissue stamp mill is used for conducting homogenizing at a high speed for two times, and homogenizing is conducted 10 min each time; and prepared homogenate is frozen at the temperature of minus 20 DEG C, freezing and thawing are conducted repeatedly for five times, centrifuging is conducted after the last time of thawing, supernatant is taken and put into a dialysis bag, the supernatant is dialyzed overnight under the environment of 0 DEG C to 4 DEG C through pyrogen-free cold normal saline, dialysate outside the bag is collected and is subjected to filtration sterilization through a filtering film, and the dialysate is subjected to sterile subpackaging and is then subjected to freezing preservation. After the biological immune preparation enters an organism, the effect of the biological immune preparation can be rapidly developed and can last for several months or even longer, the immune antibody level of the vaccine is effectively improved, the biological immune preparation can be rapidly and completely absorbed by the organism without any residue, weight increasing is obvious after the biological immune preparation is injected into the organism, and a goat can be lively in spirit.

The invention discloses a livestock biological immune preparation and a preparation method thereof. The effective component of the immune preparation is a specific yolk immunoglobulin composite antibody. According to the preparation method of the specific yolk immunoglobulin composite antibody, the specific yolk immunoglobulin composite antibody is prepared by taking three pathogenic bacteria k88, k99 and 987P of swine escherichia coli as antigens, and has a relatively good killing effect on three common pathogenic escherichia coli with high morbidity and high mortality in intestinal tracts. The traditional Chinese medicine composition can well regulate the balance of microbial flora in intestinal tracts, has a good prevention and treatment effect on livestock diarrhea, reduces the death rate of livestock, and is suitable for large-scale production and clinical application.